Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 9c; Approves $75M Stock Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks gain, oil prices slide
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results
August 9, 2016 6:50 AM EDT
-- Bendeka market share grows to 80% --
-- Positive FDA
meeting on Ryanodex for EHS --
-- Eagle purchases Ryanodex
royalty --
-- Announces $75 million share repurchase
program --
-- Q2 EPS increases to $0.84 per basic and $0.80
per diluted, Total Revenue $40.9 million --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three- and six-months ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include:
Business Highlights:... More
Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission
August 9, 2016 6:45 AM EDT-- Hajj Study Results Sufficient for Human Data in Filing --
-- Hybrid Rule (Human and Animal Data) Reaffirmed --
-- Only Completion of Ongoing Animal Studies Required for Submission--
-- Eagle Purchases Royalty Rights to Ryanodex Portfolio --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals (Eagle or the Company) (NASDAQ: EGRX) today announced that the U.S. Food and Drug Administration ("FDA") has determined that no additional human safety and efficacy data is required for the... More
